Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SAR445514 |
Synonyms | |
Therapy Description |
SAR445514 is a trifunctional natural killer (NK) cell engager (NKCE) that binds to NKp46 and CD16a on NK cells leading to activation and redirects NK cells towards TNFRSF17 (BCMA)-expressing tumor cells, potentially resulting in increased tumor cell killing (Cancer Res (2023) 83 (7_Supplement): 2960). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SAR445514 | SAR 445514|SAR-445514|IPH 6401|IPH-6401|IPH6401|SAR514|SAR'514 | SAR445514 is a trifunctional natural killer (NK) cell engager (NKCE) that binds to NKp46 and CD16a on NK cells leading to activation and redirects NK cells towards TNFRSF17 (BCMA)-expressing tumor cells, potentially resulting in increased tumor cell killing (Cancer Res (2023) 83 (7_Supplement): 2960). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05839626 | Phase Ib/II | SAR445514 | A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) | Recruiting | ITA | HUN | GBR | ESP | CZE | BEL | AUS | 0 |